

David H Howard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4533205/publications.pdf>

Version: 2024-02-01

109
papers

3,767
citations

147801

31
h-index

138484

58
g-index

112
all docs

112
docs citations

112
times ranked

5065
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer Survivorship and Supportive Care Economics Research: Current Challenges and Next Steps. <i>Journal of the National Cancer Institute Monographs</i> , 2022, 2022, 57-63.	2.1	3
2	Inaccurate Comparison of the COVID-19 Response in the United States and Cuba. <i>American Journal of Public Health</i> , 2022, 112, e4-e4.	2.7	0
3	Drivers of <scp>US</scp> health care spending for persons with seizures and/or epilepsies, 2010â€“2018. <i>Epilepsia</i> , 2022, 63, 2144-2154.	5.1	7
4	Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 432.e1-432.e10.	1.6	23
5	Deterrence effects of antifraud and abuse enforcement in health care. <i>Journal of Health Economics</i> , 2021, 75, 102405.	2.7	7
6	Medicare fee reductions and the overuse of intensityâ€modulated radiotherapy. <i>Health Services Research</i> , 2021, 56, 626-634.	2.0	2
7	Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer. <i>Cancer</i> , 2021, 127, 2974-2979.	4.1	6
8	The value of new drugs for advanced prostate cancer. <i>Cancer</i> , 2021, 127, 3457-3465.	4.1	6
9	Intensity-Modulated Radiation Therapy in Breast Cancer Patients Following the Release of a Choosing Wisely Recommendation. <i>Journal of the National Cancer Institute</i> , 2020, 112, 314-317.	6.3	8
10	Payments and Patient Cost Sharing for Prostate Biopsies According to Image Guidance, Practice Site and Use of Anesthesia. <i>Urology Practice</i> , 2020, 7, 138-144.	0.5	4
11	US False Claims Act Investigations of Unnecessary Percutaneous Coronary Interventions. <i>JAMA Internal Medicine</i> , 2020, 180, 1534.	5.1	6
12	Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist. <i>JAMA Oncology</i> , 2020, 6, 1102.	7.1	20
13	Radiation Oncology Alternative Payment Modelâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 999.	7.4	0
14	The eligibility and reach of the national breast and cervical cancer early detection program after implementation of the affordable care act. <i>Cancer Causes and Control</i> , 2020, 31, 473-489.	1.8	14
15	False Claims Act Liability for Overtreatment. <i>Journal of Health Politics, Policy and Law</i> , 2020, 45, 419-437.	1.9	5
16	Association Between Self-Reported Hypertension and Antihypertensive Medication Use and Cardiovascular Diseaseâ€Related Events and Expenditures Among Patients Diagnosed With Hypertension. <i>Public Health Reports</i> , 2019, 134, 493-501.	2.5	2
17	Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1039.	7.4	20
18	Alternative Payment for Radiation Oncology. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1859.	7.4	17

#	ARTICLE	IF	CITATIONS
19	Relationship Between Adherence to Antihypertensive Medication Regimen and Out-of-Pocket Costs Among People Aged 35 to 64 With Employer-Sponsored Health Insurance. <i>Preventing Chronic Disease</i> , 2019, 16, E32.	3.4	10
20	Physician age and the abandonment of episiotomy. <i>Health Services Research</i> , 2019, 54, 650-657.	2.0	10
21	Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 181.e15-181.e21.	1.6	6
22	The Living Donor Lost Wages Trial: Study Rationale and Protocol. <i>Current Transplantation Reports</i> , 2018, 5, 45-54.	2.0	7
23	Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States. <i>Urology</i> , 2018, 117, 57-63.	1.0	43
24	Racial/ethnic disparities in waitlisting for deceased donor kidney transplantation 1 year after implementation of the new national kidney allocation system. <i>American Journal of Transplantation</i> , 2018, 18, 1936-1946.	4.7	84
25	Physician Reimbursement for Prostate Biopsies Falls as Procedures Shift From Offices to Facilities. <i>Urology</i> , 2018, 115, 96-101.	1.0	1
26	Trends in transfusion rates after the FOCUS trial. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 113-120.	1.4	3
27	SUBSIDIZING ALTRUISM IN LIVING ORGAN DONATION. <i>Economic Inquiry</i> , 2018, 56, 398-423.	1.8	11
28	Does Bad News Travel Faster? On the Determinants of Medical Technology Abandonment. <i>Journal of Human Capital</i> , 2018, 12, 569-603.	1.3	4
29	Implementation of Florida Long Term Care Emergency Preparedness Portal Web Site, 2015â€“2017. <i>American Journal of Public Health</i> , 2018, 108, S399-S401.	2.7	1
30	Trends in the Use of Knee Arthroscopy in Adults. <i>JAMA Internal Medicine</i> , 2018, 178, 1557.	5.1	28
31	Mandatory Shared Decision Making by the Centers for Medicare & Medicaid Services for Cardiovascular Procedures and Other Tests. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 641.	7.4	56
32	The Living Donor Lost Wages Trial: Study Rationale and Protocol. <i>Current Transplantation Reports</i> , 2018, 5, 45-54.	2.0	2
33	Provider-owned insurers in the individual market. <i>American Journal of Managed Care</i> , 2018, 24, e393-e398.	1.1	1
34	Selective Hearing: Physicianâ€™Ownership and Physiciansâ€™™ Response to New Evidence. <i>Journal of Economics and Management Strategy</i> , 2017, 26, 152-168.	0.8	9
35	Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines. <i>Journal of Urology</i> , 2017, 198, 1046-1053.	0.4	6
36	Association Between Combined <i>TMPRSS2:ERG</i> and <i>PCA3</i> RNA Urinary Testing and Detection of Aggressive Prostate Cancer. <i>JAMA Oncology</i> , 2017, 3, 1085.	7.1	120

#	ARTICLE	IF	CITATIONS
37	New Kidney Allocation System Associated With Increased Rates Of Transplants Among Black And Hispanic Patients. <i>Health Affairs</i> , 2017, 36, 1078-1085.	5.2	79
38	Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study. <i>Future Oncology</i> , 2017, 13, 2021-2033.	2.4	4
39	Mammography rates after the 2009 revision to the United States Preventive Services Task Force breast cancer screening recommendation. <i>Cancer Causes and Control</i> , 2017, 28, 41-48.	1.8	16
40	Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 1570-1580.	1.3	8
41	Provider-owned insurers. <i>American Journal of Managed Care</i> , 2017, 23, 566-567.	1.1	0
42	Absenteeism and Employer Costs Associated With Chronic Diseases and Health Risk Factors in the US Workforce. <i>Preventing Chronic Disease</i> , 2016, 13, E141.	3.4	70
43	Capsule Commentary on Mehta et al. Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System. <i>Journal of General Internal Medicine</i> , 2016, 31, 1356-1356.	2.6	2
44	The accuracy of claims data for measuring transfusion rates. <i>Transfusion Medicine</i> , 2016, 26, 457-459.	1.1	10
45	New Anticancer Drugs Associated With Large Increases In Costs And Life Expectancy. <i>Health Affairs</i> , 2016, 35, 1581-1587.	5.2	37
46	Contrary To Conventional Wisdom, Physicians Abandoned A Breast Cancer Treatment After A Trial Concluded It Was Ineffective. <i>Health Affairs</i> , 2016, 35, 1309-1315.	5.2	17
47	Sociodemographic disparities in treatment and survival of small localized renal cell carcinoma: surgical resection versus thermal ablation. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 441-452.	1.4	12
48	Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. <i>Future Oncology</i> , 2016, 12, 183-198.	2.4	8
49	Perspectives in Oncology Drug Pricing—Reply. <i>JAMA Oncology</i> , 2016, 2, 402.	7.1	0
50	Hospital and skilled nursing facility patient flows during Hurricane Katrina and the Midwest floods of 2008. <i>Health Systems</i> , 2015, 4, 29-40.	1.2	2
51	Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening. <i>Medical Care</i> , 2015, 53, 630-638.	2.4	12
52	Comorbidities, smoking status, and life expectancy among individuals eligible for lung cancer screening. <i>Cancer</i> , 2015, 121, 4341-4347.	4.1	59
53	Pricing in the Market for Anticancer Drugs. <i>Journal of Economic Perspectives</i> , 2015, 29, 139-162.	5.9	379
54	Hospital Readmission Is Associated With Poor Survival After Esophagectomy for Esophageal Cancer. <i>Annals of Thoracic Surgery</i> , 2015, 99, 292-297.	1.3	40

#	ARTICLE	IF	CITATIONS
55	Influenza vaccination rates and beliefs about vaccination among nursing home employees. <i>American Journal of Infection Control</i> , 2015, 43, 100-106.	2.3	36
56	Cervical cancer screening of underserved women in the United States: results from the National Breast and Cervical Cancer Early Detection Program, 1997â€“2012. <i>Cancer Causes and Control</i> , 2015, 26, 671-686.	1.8	43
57	Breast cancer screening of underserved women in the USA: results from the National Breast and Cervical Cancer Early Detection Program, 1998â€“2012. <i>Cancer Causes and Control</i> , 2015, 26, 657-668.	1.8	42
58	Producing Evidence to Reduce Low-Value Care. <i>JAMA Internal Medicine</i> , 2015, 175, 1893.	5.1	18
59	Necitumumab in Metastatic Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2015, 1, 1293.	7.1	43
60	End-of-Life Medical Costs of Medicaid Cancer Patients. <i>Health Services Research</i> , 2015, 50, 690-709.	2.0	25
61	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 658-658.	1.6	1
62	Changes in Geographic Variation in the Use of Percutaneous Coronary Intervention for Stable Ischemic Heart Disease After Publication of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 125-130.	2.2	20
63	Eliminating costâ€šaring requirements for colon cancer screening in <sc>M</sc>edicare. <i>Cancer</i> , 2014, 120, 3850-3852.	4.1	8
64	Adverse Effects of Prohibiting Narrow Provider Networks. <i>New England Journal of Medicine</i> , 2014, 371, 591-593.	27.0	22
65	Drug Companies' Patient-Assistance Programs â€” Helping Patients or Profits?. <i>New England Journal of Medicine</i> , 2014, 371, 97-99.	27.0	44
66	Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 219-225.	2.3	35
67	Trends in <sc>PCI</sc> Volume after Negative Results from the <sc>COURAGE</sc> Trial. <i>Health Services Research</i> , 2014, 49, 153-170.	2.0	31
68	Impact of Negative Clinical Trial Results for Vertebroplasty on Vertebral Augmentation Procedure Rates. <i>Journal of the American College of Surgeons</i> , 2014, 219, 525-533e1.	0.5	17
69	Can major systematic reviews influence practice patterns? A case study of episiotomy trends. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 1285-1293.	1.7	7
70	Prostate Cancer Screening In Men Ages 75 And Older Fell By 8 Percentage Points After Task Force Recommendation. <i>Health Affairs</i> , 2013, 32, 596-602.	5.2	34
71	THE EFFECT OF CADAVERIC KIDNEY DONATIONS ON LIVING KIDNEY DONATIONS: AN INSTRUMENTAL VARIABLES APPROACH. <i>Economic Inquiry</i> , 2013, 51, 1696-1714.	1.8	13
72	Impact of Medicaid reimbursement and eligibility policies on receipt of cancer screening.. <i>Journal of Clinical Oncology</i> , 2013, 31, 6514-6514.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Cancer Treatment for Dual Eligibles: What Are the Costs and Who Pays?. American Journal of Cancer Science, 2013, 2, 2013010007.	0.0	0
74	Hospitalization Rates Among Dialysis Patients During Hurricane Katrina. Prehospital and Disaster Medicine, 2012, 27, 325-329.	1.3	25
75	Evidence Of No Benefit From Knee Surgery For Osteoarthritis Led To Coverage Changes And Is Linked To Decline In Procedures. Health Affairs, 2012, 31, 2242-2249.	5.2	20
76	Serious Health Events and Discontinuation of Routine Cancer Screening. Medical Decision Making, 2012, 32, 627-635.	2.4	7
77	Comparative Effectiveness Research, Technological Abandonment, and Health Care Spending. Advances in Health Economics and Health Services Research, 2012, 23, 103-121.	0.2	12
78	Declines in Prostate Cancer Incidence After Changes in Screening Recommendations. Archives of Internal Medicine, 2012, 172, 1267.	3.8	28
79	Mammography rates after the 2009 US Preventive Services Task Force breast cancer screening recommendation. Preventive Medicine, 2012, 55, 485-487.	3.4	47
80	Nursing homesâ€™ preparedness plans and capabilities. American Journal of Disaster Medicine, 2012, 7, 127-135.	0.3	4
81	WAITING TIME AS A PRICE FOR DECEASED DONOR KIDNEYS*. Contemporary Economic Policy, 2011, 29, 295-303.	1.7	7
82	Abandonment of High-Dose Chemotherapy/Hematopoietic Cell Transplants for Breast Cancer Following Negative Trial Results. Health Services Research, 2011, 46, 1762-1777.	2.0	28
83	Realigning Incentives for Developing and Pricing New Anticancer Treatments. JAMA - Journal of the American Medical Association, 2011, 305, 2347.	7.4	3
84	The impact of a national program to provide free mammograms to low-income, uninsured women on breast cancer mortality rates. Cancer, 2010, 116, 4456-4462.	4.1	25
85	Understanding recent increases in chronic disease treatment rates: more disease or more detection?. Health Economics, Policy and Law, 2010, 5, 411-435.	1.8	14
86	The Value of New Chemotherapeutic Agents for Metastatic Colorectal Cancer. Archives of Internal Medicine, 2010, 170, 537.	3.8	41
87	Comparative Effectiveness Research and Cancer Screening in the United States and Europe. Medical Decision Making, 2009, 29, NP12-NP13.	2.4	0
88	Cancer Screening And Age In The United States And Europe. Health Affairs, 2009, 28, 1838-1847.	5.2	26
89	The impact of detection and treatment on lifetime medical costs for patients with precancerous polyps and colorectal cancer. Health Economics (United Kingdom), 2009, 18, 1381-1393.	1.7	16
90	Use of Cost-Effectiveness Analysis to Determine Inventory Size for a National Cord Blood Bank. Medical Decision Making, 2008, 28, 243-253.	2.4	36

#	ARTICLE	IF	CITATIONS
91	Hospital Quality and Selective Contracting: Evidence from Kidney Transplantation. Forum for Health Economics and Policy, 2008, 11, 2.	0.8	11
92	Just Health: Meeting Health Needs Fairly. JAMA - Journal of the American Medical Association, 2008, 299, 2568.	7.4	0
93	Should We Promote Organ Donor Registries When So Few Registrants Will End Up Being Donors?. Medical Decision Making, 2007, 27, 243-249.	2.4	29
94	Producing Organ Donors. Journal of Economic Perspectives, 2007, 21, 25-36.	5.9	478
95	Does Quality Improvement Work? Evaluation of the Organ Donation Breakthrough Collaborative. Health Services Research, 2007, 42, 2160-2173.	2.0	65
96	The Relationship between Ex Ante Mortality Risk and End-of-Life Medical Costs. Applied Health Economics and Health Policy, 2006, 5, 37-44.	2.1	5
97	Do Report Cards Influence Hospital Choice? The Case of Kidney Transplantation. Inquiry (United Tj ETQq1 1 0.784314 rgBT /Overlock 11 0,9 36	0.9	36
98	Impact of health literacy on socioeconomic and racial differences in health in an elderly population. Journal of General Internal Medicine, 2006, 21, 857-861.	2.6	257
99	Quality and Consumer Choice in Healthcare: Evidence from Kidney Transplantation. BE Journal of Economic Analysis and Policy, 2006, 5, 1349.	0.3	31
100	Rising Medicare Costs: The Authors Respond. Health Affairs, 2006, 25, W391-W392.	5.2	0
101	The Economic Burden of Drug Resistance. Clinical Infectious Diseases, 2005, 41, S283-S286.	5.8	40
102	Life expectancy and the value of early detection. Journal of Health Economics, 2005, 24, 891-906.	2.7	40
103	The impact of low health literacy on the medical costs of Medicare managed care enrollees. American Journal of Medicine, 2005, 118, 371-377.	1.5	391
104	Initial and Follow-up Costs by Treatment Outcome for Children With Respiratory Infections. Pediatrics, 2004, 113, 1352-1356.	2.1	11
105	Resistance-induced antibiotic substitution. Health Economics (United Kingdom), 2004, 13, 585-595.	1.7	26
106	National estimates of medical costs incurred by nonelderly cancer patients. Cancer, 2004, 100, 883-891.	4.1	37
107	The Global Impact of Drug Resistance. Clinical Infectious Diseases, 2003, 36, S4-S10.	5.8	90
108	Why do transplant surgeons turn down organs?. Journal of Health Economics, 2002, 21, 957-969.	2.7	57

#	ARTICLE	IF	CITATIONS
109	Measuring the Economic Costs of Antimicrobial Resistance in Hospital Settings: Summary of the Centers for Disease Control and Preventionâ€™ Emory Workshop. <i>Clinical Infectious Diseases</i> , 2001, 33, 1573-1578.	5.8	66